vs
EXACT SCIENCES CORP（EXAS）与PTC Inc.（PTC）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是PTC Inc.的1.1倍（$878.4M vs $774.3M），PTC Inc.净利率更高（76.3% vs -9.8%，领先86.1%），EXACT SCIENCES CORP同比增速更快（23.1% vs 21.7%），PTC Inc.自由现金流更多（$318.0M vs $120.4M），过去两年PTC Inc.的营收复合增速更高（22.2% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
PTC是1985年成立的美国计算机软件与服务企业，总部位于马萨诸塞州波士顿。公司1988年率先推出参数化关联特征驱动的三维CAD建模软件，1998年发布基于互联网的产品生命周期管理（PLM）产品，目前面向合作伙伴与开发者提供物联网、增强现实（AR）平台及相关产品服务。
EXAS vs PTC — 直观对比
营收规模更大
EXAS
是对方的1.1倍
$774.3M
营收增速更快
EXAS
高出1.4%
21.7%
净利率更高
PTC
高出86.1%
-9.8%
自由现金流更多
PTC
多$197.6M
$120.4M
两年增速更快
PTC
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $774.3M |
| 净利润 | $-86.0M | $590.7M |
| 毛利率 | 70.1% | 99.1% |
| 营业利润率 | -9.4% | 38.2% |
| 净利率 | -9.8% | 76.3% |
| 营收同比 | 23.1% | 21.7% |
| 净利润同比 | 90.1% | 141.2% |
| 每股收益（稀释后） | $-0.45 | $4.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPTC
| Q1 26 | — | $774.3M | ||
| Q4 25 | $878.4M | $685.8M | ||
| Q3 25 | $850.7M | $893.8M | ||
| Q2 25 | $811.1M | $643.9M | ||
| Q1 25 | $706.8M | $636.4M | ||
| Q4 24 | $713.4M | $565.1M | ||
| Q3 24 | $708.7M | $626.5M | ||
| Q2 24 | $699.3M | $518.6M |
净利润EXASPTC
| Q1 26 | — | $590.7M | ||
| Q4 25 | $-86.0M | $166.5M | ||
| Q3 25 | $-19.6M | $347.8M | ||
| Q2 25 | $-1.2M | $141.3M | ||
| Q1 25 | $-101.2M | $162.6M | ||
| Q4 24 | $-864.6M | $82.2M | ||
| Q3 24 | $-38.2M | $126.5M | ||
| Q2 24 | $-15.8M | $69.0M |
毛利率EXASPTC
| Q1 26 | — | 99.1% | ||
| Q4 25 | 70.1% | 82.8% | ||
| Q3 25 | 68.6% | 86.9% | ||
| Q2 25 | 69.3% | 82.9% | ||
| Q1 25 | 70.8% | 83.3% | ||
| Q4 24 | 69.0% | 80.2% | ||
| Q3 24 | 69.4% | 82.0% | ||
| Q2 24 | 69.8% | 78.4% |
营业利润率EXASPTC
| Q1 26 | — | 38.2% | ||
| Q4 25 | -9.4% | 32.2% | ||
| Q3 25 | -3.0% | 48.5% | ||
| Q2 25 | -0.3% | 32.6% | ||
| Q1 25 | -13.6% | 35.1% | ||
| Q4 24 | -122.8% | 20.4% | ||
| Q3 24 | -5.6% | 31.0% | ||
| Q2 24 | -3.8% | 18.5% |
净利率EXASPTC
| Q1 26 | — | 76.3% | ||
| Q4 25 | -9.8% | 24.3% | ||
| Q3 25 | -2.3% | 38.9% | ||
| Q2 25 | -0.1% | 21.9% | ||
| Q1 25 | -14.3% | 25.6% | ||
| Q4 24 | -121.2% | 14.6% | ||
| Q3 24 | -5.4% | 20.2% | ||
| Q2 24 | -2.3% | 13.3% |
每股收益（稀释后）EXASPTC
| Q1 26 | — | $4.98 | ||
| Q4 25 | $-0.45 | $1.39 | ||
| Q3 25 | $-0.10 | $2.88 | ||
| Q2 25 | $-0.01 | $1.17 | ||
| Q1 25 | $-0.54 | $1.35 | ||
| Q4 24 | $-4.69 | $0.68 | ||
| Q3 24 | $-0.21 | $1.05 | ||
| Q2 24 | $-0.09 | $0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $3.9B |
| 总资产 | $5.9B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASPTC
| Q1 26 | — | $439.1M | ||
| Q4 25 | $964.7M | $209.7M | ||
| Q3 25 | $1.0B | $184.4M | ||
| Q2 25 | $858.4M | $199.3M | ||
| Q1 25 | $786.2M | $235.2M | ||
| Q4 24 | $1.0B | $196.3M | ||
| Q3 24 | $1.0B | $265.8M | ||
| Q2 24 | $946.8M | $247.7M |
总债务EXASPTC
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.3B |
股东权益EXASPTC
| Q1 26 | — | $3.9B | ||
| Q4 25 | $2.4B | $3.8B | ||
| Q3 25 | $2.5B | $3.8B | ||
| Q2 25 | $2.5B | $3.5B | ||
| Q1 25 | $2.4B | $3.4B | ||
| Q4 24 | $2.4B | $3.2B | ||
| Q3 24 | $3.2B | $3.2B | ||
| Q2 24 | $3.2B | $3.0B |
总资产EXASPTC
| Q1 26 | — | $6.5B | ||
| Q4 25 | $5.9B | $6.4B | ||
| Q3 25 | $5.9B | $6.6B | ||
| Q2 25 | $5.8B | $6.2B | ||
| Q1 25 | $5.7B | $6.2B | ||
| Q4 24 | $5.9B | $6.1B | ||
| Q3 24 | $6.7B | $6.4B | ||
| Q2 24 | $6.7B | $6.1B |
负债/权益比EXASPTC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.31× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.38× | ||
| Q2 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $320.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $318.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 41.1% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 0.54× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $927.9M |
8季度趋势，按日历期对齐
经营现金流EXASPTC
| Q1 26 | — | $320.9M | ||
| Q4 25 | $151.7M | $269.7M | ||
| Q3 25 | $219.9M | $104.0M | ||
| Q2 25 | $89.0M | $243.9M | ||
| Q1 25 | $30.8M | $281.3M | ||
| Q4 24 | $47.1M | $238.4M | ||
| Q3 24 | $138.7M | $98.1M | ||
| Q2 24 | $107.1M | $213.8M |
自由现金流EXASPTC
| Q1 26 | — | $318.0M | ||
| Q4 25 | $120.4M | $267.4M | ||
| Q3 25 | $190.0M | $100.5M | ||
| Q2 25 | $46.7M | $242.0M | ||
| Q1 25 | $-365.0K | $278.5M | ||
| Q4 24 | $10.7M | $235.7M | ||
| Q3 24 | $112.6M | $93.6M | ||
| Q2 24 | $71.2M | $212.2M |
自由现金流率EXASPTC
| Q1 26 | — | 41.1% | ||
| Q4 25 | 13.7% | 39.0% | ||
| Q3 25 | 22.3% | 11.2% | ||
| Q2 25 | 5.8% | 37.6% | ||
| Q1 25 | -0.1% | 43.8% | ||
| Q4 24 | 1.5% | 41.7% | ||
| Q3 24 | 15.9% | 14.9% | ||
| Q2 24 | 10.2% | 40.9% |
资本支出强度EXASPTC
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.3% | ||
| Q3 25 | 3.5% | 0.4% | ||
| Q2 25 | 5.2% | 0.3% | ||
| Q1 25 | 4.4% | 0.4% | ||
| Q4 24 | 5.1% | 0.5% | ||
| Q3 24 | 3.7% | 0.7% | ||
| Q2 24 | 5.1% | 0.3% |
现金转化率EXASPTC
| Q1 26 | — | 0.54× | ||
| Q4 25 | — | 1.62× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 1.73× | ||
| Q1 25 | — | 1.73× | ||
| Q4 24 | — | 2.90× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 3.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PTC
| Recurring revenue | $743.4M | 96% |
| Other | $24.0M | 3% |
| Perpetual license | $6.9M | 1% |
